You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

High-grade Ta or T1 disease

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Recurrent Bladder Carcinoma, Bladder Cancer Stage 0, Bladder Cancer Stage I Trial in Los Angeles (Pharmacokinetic Study,

Not yet recruiting
  • Recurrent Bladder Carcinoma
  • +2 more
  • Pharmacokinetic Study
  • Recombinant EphB4-HSA Fusion Protein
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Jan 31, 2023

Bladder Carcinoma in Situ (CIS) Trial (ONCOFID P-B (PACLITAXEL-HYALURONIC ACID))

Recruiting
  • Bladder Carcinoma in Situ (CIS)
  • ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
  • New Orleans, Louisiana
    Ochsner Clinic Foundation
Jan 18, 2023

Burkitt Lymphoma, High-grade B-cell Lymphoma, T-cell/Histocyte-rich Large B-cell Lymphoma Trial run by the NCI (Rituximab,

Suspended
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Non-muscle Invasive Bladder Cancer Trial in Hanover, Mount Laurel, Rochester (TARA-002)

Recruiting
  • Non-muscle Invasive Bladder Cancer
  • TARA-002
  • Los Angeles, California
  • +11 more
Jan 31, 2023

Bladder Cancer, Bladder Urothelial Carcinoma Trial in Toronto (re-TURBT, 6 weeks BCG instillation)

Terminated
  • Bladder Cancer
  • Bladder Urothelial Carcinoma
  • re-TURBT
  • 6 weeks BCG instillation
  • Toronto, Ontario, Canada
    University Health Network
Apr 12, 2022

Glioma Trial in Ottawa (MR perfusion imaging)

Completed
  • Glioma
  • MR perfusion imaging
  • Ottawa, Ontario, Canada
    The Ottawa Hospital
Oct 7, 2021

B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes Trial in New York (19(T2)28z1xx TRAC T cell)

Recruiting
  • B-Cell Lymphoma
  • +4 more
  • 19(T2)28z1xx TRAC T cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Feb 24, 2023

Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,

Active, not recruiting
  • Adult Grade III Lymphomatoid Granulomatosis
  • +23 more
  • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023

B-Cell Non-Hodgkin Lymphoma, DLBCL, Not Otherwise Specified, High Grade B-Cell Lymphoma Trial in Seattle (Acalabrutinib,

Recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Dec 9, 2022

Recurrent ALK Positive Large B-Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between

Not yet recruiting
  • Recurrent ALK Positive Large B-Cell Lymphoma
  • +28 more
  • Biospecimen Collection
  • +5 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Aug 17, 2022

Dyslipidemia in Patients at High Risk and Very High Risk of

Recruiting
  • Secondary Prevention
  • +2 more
  • application
  • Leon, Guanajuato, Mexico
    Umae Cmn T1
Sep 13, 2022

Non-muscle Invasive Bladder Cancer Trial (TARA-002)

Not yet recruiting
  • Non-muscle Invasive Bladder Cancer
  • TARA-002
  • (no location specified)
Jul 14, 2023

Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia Trial in Seattle (Cladribine, Cytarabine,

Recruiting
  • Acute Biphenotypic Leukemia
  • +11 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 18, 2022

Bladder Cancer Trial in Worldwide (TAR-200, Cetrelimab, BCG Vesiculture)

Not yet recruiting
  • Bladder Cancer
  • Scottsdale, Arizona
  • +241 more
Feb 9, 2023

Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic Hodgkin Lymphoma, Recurrent

Not yet recruiting
  • Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma
  • +21 more
  • Biopsy
  • +8 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Apr 7, 2023

Anal Dysplasia, Human Papillomavirus, Anal Cancer Trial in Vancouver, Ottawa, Toronto (The Hyfrecator ® 2000 Electrosurgical

Terminated
  • Anal Dysplasia
  • +2 more
  • The Hyfrecator ® 2000 Electrosurgical System
  • Observation Alone
  • Vancouver, British Columbia, Canada
  • +3 more
Jun 9, 2022

Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor, CNS Germ Cell Tumor Trial in Houston (drug, procedure, biological)

Recruiting
  • Anaplastic Ependymoma
  • +14 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 17, 2022

Recurrent Chronic Lymphocytic Leukemia, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Seattle (Nivolumab)

Recruiting
  • Recurrent Chronic Lymphocytic Leukemia
  • +17 more
  • Nivolumab
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 16, 2022

Non Muscular Invasive Bladder Cancer Trial in Worldwide (CG0070, n-dodecyl-B-D-maltoside)

Recruiting
  • Non Muscular Invasive Bladder Cancer
  • CG0070
  • n-dodecyl-B-D-maltoside
  • Homewood, Alabama
  • +58 more
Jun 16, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent DLBCL, Recurrent High Grade B-Cell Lymphoma Trial in Houston (Anakinra,

Active, not recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +8 more
  • Anakinra
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 22, 2022

Healthy, Obesity, Diabetes Trial run by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (MR Imaging

Recruiting
  • Healthy
  • +4 more
  • MR Imaging Techniques - 1
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Aug 24, 2022

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

Bladder Cancer Trial in Canada, United States (Vicinium)

Active, not recruiting
  • Bladder Cancer
  • Vicinium
  • Birmingham, Alabama
  • +69 more
Jun 10, 2021

Non Muscle Invasive Bladder Cancer Trial in Korea, Republic of, United States (CG0070, Pembrolizumab Injection,

Recruiting
  • Non Muscle Invasive Bladder Cancer
  • CG0070
  • +2 more
  • Phoenix, Arizona
  • +20 more
Jun 16, 2022

Bladder Cancer Recurrent, Non-Invasive Bladder Urothelial Carcinoma Trial in Ankara, Istanbul, Izmir

Recruiting
  • Bladder Cancer Recurrent
  • Non-Invasive Bladder Urothelial Carcinoma
    • Ankara, Turkey
    • +2 more
    Apr 10, 2022